Home

Nevro Corp. Common Stock (NVRO)

5.7200
0.00 (0.00%)

Nevro Corp is a global medical device company that specializes in developing innovative solutions for chronic pain management

The company focuses on providing advanced spinal cord stimulation systems designed to improve the quality of life for patients suffering from various types of neuropathic pain. With a commitment to research and development, Nevro aims to deliver cutting-edge technologies that enhance patient outcomes and address unmet medical needs in the field of pain relief. By pioneering therapies and treatment options, Nevro plays a crucial role in transforming how chronic pain is managed in clinical practice.

SummaryNewsPress ReleasesChartHistoricalFAQ
Demystifying Nevro: Insights From 11 Analyst Reviewsbenzinga.com
Via Benzinga · February 7, 2025
Where Nevro Stands With Analystsbenzinga.com
Via Benzinga · December 18, 2024
Morgan Stanley Maintains Positive MedTech Outlook Despite Setbacks in 2024, Upgrades Intuitive Surgical And Stryker, Downgrades Nevro And Glaukosbenzinga.com
Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via Benzinga · December 2, 2024
What Analysts Are Saying About Nevro Stockbenzinga.com
Via Benzinga · December 2, 2024
12 Health Care Stocks Moving In Tuesday's Pre-Market Sessionbenzinga.com
Via Benzinga · November 12, 2024
Peeling Back The Layers: Exploring Nevro Through Analyst Insightsbenzinga.com
Via Benzinga · November 12, 2024
A Look Ahead: Nevro's Earnings Forecastbenzinga.com
Via Benzinga · November 8, 2024
Breaking Down Nevro: 10 Analysts Share Their Viewsbenzinga.com
Via Benzinga · October 1, 2024
Assessing Nevro: Insights From 9 Financial Analystsbenzinga.com
Via Benzinga · August 8, 2024
Why Medical Device Firm Nevro Stock Is Trading Higher On Tuesdaybenzinga.com
Nevro stock rises as it gains CE Mark for its HFX iQ SCS system, the first with AI-based personalized pain relief. 2024 revenue outlook raised amid positive earnings.
Via Benzinga · November 12, 2024
Earnings Scheduled For November 11, 2024benzinga.com
Via Benzinga · November 11, 2024
Evaluating Nevro: Insights From 8 Financial Analystsbenzinga.com
Via Benzinga · August 7, 2024
Airbnb Reports Weak Earnings, Joins Cryoport, Tripadvisor, Lyft And Other Big Stocks Moving Lower In Wednesday's Pre-Market Sessionbenzinga.com
Via Benzinga · August 7, 2024
Beyond The Numbers: 6 Analysts Discuss Nevro Stockbenzinga.com
Via Benzinga · July 15, 2024
Assessing Nevro: Insights From 9 Financial Analystsbenzinga.com
Via Benzinga · May 8, 2024
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesdayinvestorplace.com
Pre-market stock movers are a hot topic on Wednesday and we have all of the latest news traders need to know about them this morning!
Via InvestorPlace · August 7, 2024
Why Fortinet Shares Are Trading Higher By Around 17%; Here Are 20 Stocks Moving Premarketbenzinga.com
Via Benzinga · August 7, 2024
NVRO Stock Earnings: Nevro Beats EPS, Misses Revenue for Q2 2024investorplace.com
NVRO stock results show that Nevro beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024
NVRO Stock Earnings: Nevro Beats EPS, Beats Revenue for Q1 2024investorplace.com
NVRO stock results show that Nevro beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 7, 2024
Where Nevro Stands With Analystsbenzinga.com
Via Benzinga · April 3, 2024
Analyst Scoreboard: 4 Ratings For Nevrobenzinga.com
Via Benzinga · February 22, 2024
Nevro: Q4 Earnings Insightsbenzinga.com
Via Benzinga · February 21, 2024
Earnings Scheduled For February 21, 2024benzinga.com
Companies Reporting Before The Bell • Gatos Silver (NYSEGATO) is estimated to report quarterly earnings at $0.09 per share on revenue of $83.00 million.
Via Benzinga · February 21, 2024
Why Nevro Stock Lagged the Market on Thursdayfool.com
Despite convincing beats on its latest set of quarterly figures, the market wasn't all that impressed with the company's latest developments.
Via The Motley Fool · February 22, 2024
What Analysts Are Saying About Nevro Stockbenzinga.com
Via Benzinga · January 12, 2024